SCHEMBL1639151

SCHEMBL1639151

C=C(c1cccc(-c2cccc(-c3ccccc3)c2OCc2ccccc2)c1)c1ccccc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 6/20 0.49
MGAM O43451 1/20 0.45
GAA P10253 1/20 0.45
SI P14410 1/20 0.45
MGAM2 Q2M2H8 1/20 0.45
MRGPRX4 Q96LA9 1/20 0.44
FFAR1 O14842 2/20 0.43
SCN9A Q15858 1/20 0.43
CYP2C9 P11712 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 1/20 0.42
PTGER4 P35408 1/20 0.41
PTGER3 P43115 1/20 0.41
PTGER2 P43116 1/20 0.41
BCHE P06276 1/20 0.40
ERN1 O75460 1/20 0.40
HTR7 P34969 1/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637711 0.92 PTGER1 (0.48) PTGER1MGAMGAASIMGAM2
SCHEMBL1639242 0.90 PTGER1 (0.44) PTGER1MGAMGAASIMGAM2
SCHEMBL1639353 0.88 SCN9A (0.47) PTGER1MGAMGAASIMGAM2
SCHEMBL12646856 0.86 PTPN11 (0.43) PTGER1L3MBTL1KDM4ELMNAMAPK1
SCHEMBL1638928 0.83 PTGER1 (0.44) PTGER1MGAMGAASIMGAM2
SCHEMBL27864148 0.83 MAOB (0.49) PTGER1MGAMGAASIMGAM2
SCHEMBL1638866 0.80 PTGER1 (0.46) PTGER1MGAMGAASIMGAM2
SCHEMBL1643985 0.80 NR1H4 (0.47) PTGER1MGAMGAASIMGAM2
SCHEMBL12646938 0.78 PTPN11 (0.42) FFAR1L3MBTL1KDM4EHTR7LMNA
SCHEMBL12726013 0.78 SCN9A (0.52) PTGER1MGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
EP-2493932-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
WO-2011056423-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098429-A1 Catalyst Compounds and Use Thereof ALOX12, THEM6, ALOX15 PTGER1 2069/4885MGAM 536/4885GAA 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.